Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data

Journal of Pharmaceutical Sciences

Volumn 104, Issue 2, 2015, Pages 536-547

  Kalonia, Cavan ^a   Kumru, Ozan S ^a   Prajapati, Indira ^a   Mathaes, Roman ^b   Engert, Julia ^b   Zhou, Shuxia ^c   Middaugh, C Russell ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Data visualization; Formulation; MAb; Microflow imaging; Morphology; Particle mass; Particle size; Protein aggregation; Stability

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; POLYSTYRENE; PROTEIN; IMMUNOGLOBULIN G; PROTEIN AGGREGATE;

ARTICLE; CALCULATION; CONTROLLED STUDY; INTERMETHOD COMPARISON; MEASUREMENT ACCURACY; MECHANICAL STRESS; MICROFLOW IMAGING; MOLECULAR IMAGING; MOLECULAR WEIGHT; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN STRUCTURE; IMAGE PROCESSING; MICROSCOPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN G; MICROSCOPY; MOLECULAR WEIGHT; PARTICLE SIZE; PROTEIN AGGREGATES;

EID: 84922952911     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24156     Document Type: Article

References (46)

1. Carpenter JF, Randolph TW, Jiskoot W, Crommelin D.J., Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D., Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
2. Glover ZW, Gennaro L, Yadav S., Demeule B, Wong PY, Sreedhara A. 2013. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 102(3):794-812.
3. Sreedhara A, Glover ZK, Piros N, Xiao N., Patel A, Kabakoff B. 2012. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci 101(1):21-30.
4. Kumru OS, Liu J, Ji J.A., Cheng W., Wang YJ, Wang T, Joshi SB, Middaugh C.R., Volkin DB. 2012. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 101(10):3636-3650.
5. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J., Narhi LO. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286(28):25118-25133.
6. Luo Q, Joubert MK, Stevenson R, Ketchem R.R., Narhi LO, Wypych J. 2011. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem 286(28):25134-25144.
7. Ripple DC, Dimitrova MN. 2012. Protein particles: What we know and what we do not know. J Pharm Sci 101(10):3568-3579.
8. Das TK. 2012. Protein particulate detection issues in biotherapeutics development-Current status. AAPS PharmSciTech 13(2):732-746.
9. Demeule B, Messick S, Shire S.J., Liu J. 2010. Characterization of particles in protein solutions: Reaching the limits of current technologies. AAPS J 12(4):708-715.
10. Narhi LO, Jiang Y, Cao S., Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10(4):373-381.
11. Patel AR, Lau D, Liu J. 2012. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. Anal Chem 84(15):6833-6840.
12. Telikepalli SN, Kumru OS, Kalonia C, Esfandiary R., Joshi SB, Middaugh CR, Volkin DB. 2014. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci 103(3):796-809.
13. Joubert MK, Hokom M, Eakin C., Zhou L, Deshpande M, Baker M.P., Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287(30):25266-25279.
14. Bi V, Jawa V, Joubert M.K., Kaliyaperumal A., Eakin C, Richmond K, Pan O., Sun J, Hokom M, Goletz TJ, Wypych J, Zhou L, Kerwin BA, Narhi LO, Arora T. 2013. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J Pharm Sci 102(10):3545-3555.
15. Torosantucci R, Brinks V, Kijanka G., Halim LA, Sauerborn M, Schellekens H, Jiskoot W. 2014. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. J Pharm Sci 103(5):1367-1374.
16. Brinks V, Weinbuch D, Baker M., Dean Y, Stas P, Kostense S., Rup B, Jiskoot W. 2013. Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 30(7):1719-1728.
17. Barnard JG, Singh S, Randolph T.W., Carpenter JF. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100(2):492-503.
18. Simler BR, Hui G, Dahl J.E., Perez-Ramirez B.2012. Mechanistic complexity of subvisible particle formation: Links to protein aggregation are highly specific. J Pharm Sci 101(11):4140-4154.
19. Wuchner K, Buchler J, Spycher R., Dalmonte P, Volkin DB. 2010. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 99(8):3343-3361.
20. Chi EY, Krishnan S, Randolph T.W., Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325-1336.
21. Philo JS, Arakawa T. 2009. Mechanisms of protein aggregation. Curr Pharm Biotechnol 10(4):348-351.
22. Kalonia C, Kumru OS, Kim J.H., Middaugh CR, Volkin DB. 2013. Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques. J Pharm Sci 102(12):4256-4267.
23. Arosio P, Rima S, Morbidelli M. 2013. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: From oligomers to larger aggregates. Pharm Res 30(3):641-654.
24. Neudecker P, Robustelli P, Cavalli A., Walsh P, Lundstrom P, Zarrine-Afsar A, Sharpe S., Vendruscolo M, Kay LE. 2012. Structure of an intermediate state in protein folding and aggregation. Science 336(6079):362-366.
25. Brummitt RK, Nesta DP, Chang L, Chase S.F., Laue TM, Roberts CJ. 2011. Nonnative aggregation of an IgG1 antibody in acidic conditions: Part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. J Pharm Sci 100(6):2087-2103.
26. Kroetsch AM, Sahin E, Wang H.Y., Krizman S., Roberts CJ. 2012. Relating particle formationtosalt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A. J Pharm Sci 101(10):3651-3660.
27. Bai S, Murugesan Y, Vlasic M., Karpes LB, Brader ML. 2013. Effects of submicron particles on formation of micron-sized particles during long-term storage of an interferon-beta-1a solution. J Pharm Sci 102(2):347-351.
28. Zolls S, Gregoritza M, Tantipolphan R., Wiggenhorn M, Winter G, Friess W., Hawe A. 2013. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. J Pharm Sci 102(5):1434-1446.
29. Werk T, Volkin DB, Mahler HC. 2014. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. Eur J Pharm Sci 53:95-108.
30. Scherer TM, Leung S, Owyang L., Shire SJ. 2012. Issues and challenges of subvisible and submicron particulate analysis in protein solutions. AAPS J 14(2):236-243.
31. Sharma DK, King D, Merchant C. 2011. Reference material development for calibration and verification of image-based particle analyzers. Int J Pharm 416(1):293-295.
32. Murphy DB, Davidson MW. 2012. Fundamentals of Light Microscopy and Electronic Imaging, Second Edition, John Wiley & Sons, Inc., Hoboken, NJ, USA. doi:10.1002/9781118382905.
33. Brown L. 2011. Characterizing biologics using dynamic imaging particle analysis. Biopharm Int 24(8):S4-S9.
34. Sharma DK, Oma P, Pollo M.J., Sukumar M. 2010. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. J Pharm Sci 99(6):2628-2642.
35. Sharma DK, King D, Oma P., Merchant C. 2010. Micro-flow imaging: Flow microscopy applied to sub-visible particulate analysis in protein formulations. AAPS J 12(3):455-464.
36. Strehl R, Rombach-Riegraf V, Diez M., Egodage K, Bluemel M, Jeschke M., Koulov A. 2011. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: A novel multiparamet-ric image filter for sub-visible particles in microflow imaging analysis. J Pharm Res 29(2):594-602.
37. Quillin ML, Matthews BW. 2000. Accurate calculation of the density of proteins. Acta Crystallogr D Biol Crystallogr 56(Pt 7):791-794.
38. Champion JA, Katare YK, Mitragotri S. 2007. Making polymeric micro- and nanoparticles of complex shapes. Proc Natl Acad Sci USA 104(29):11901-11904.
39. Mach H, Middaugh CR. 2011. Ultraviolet spectroscopy as a tool in therapeutic protein development. J Pharm Sci 100(4):1214-1227.
40. Fischer H, Polikarpov I, Craievich AF. 2004. Average protein density is a molecular-weight-dependent function. Protein Sci 13(10):2825-2828.
41. Ripple D, Wayment JR, Carrier MJ. 2011. Standards for the optical detection of protein particles. Am Pharm Rev July/August 90-96.
42. White ET, Tan WH, Ang J.M., Tait S., Litster JD. 2007. The density of a protein crystal. Powder Technol 179(1-2):55-58.
43. Zhao HY, Brown PH, Schuckt P. 2011. Onthe distribution of protein refractive index increments. Biophys J 100(9):2309-2317.
44. Barer R, Tkaczyk S. 1954. Refractive index of concentrated protein solutions. Nature 173(4409):821-822.
45. Ball V, Ramsden JJ. 1998. Buffer dependence of refractive index increments of protein solutions. Biopolymers 46(7):489-492.
46. Voros J. 2004. The density and refractive index of adsorbing protein layers. Biophys J 87(1):553-561.